Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Description: All Cause Mortality at 28 days
Measure: Mortality at 28 days Time: 28 days after enrollmentDescription: To assess the effect of Pulmozyme® on the severity of respiratory failure, systemic inflammatory response, and multi-organ failure.
Measure: Systemic Therapeutic Response Time: 5 days after enrollmentDescription: Proportion of patients alive and free of invasive mechanical ventilation at 28 days invasive mechanical ventilation at 28 days
Measure: Respiratory Response Time: 28 daysDescription: Proportion of patients alive and discharged from the ICU at 28 days discharged from the ICU at 28 days
Measure: Legnth of ICU Stay Time: 28 daysDescription: Proportion of patients alive and discharged from the hospital at 28 days
Measure: Legnth of Hospital Stay Time: 28 daysDescription: Alive, respiratory failure-free days at 28 days
Measure: Respiratory Response Time: 28 daysDescription: Pulmonary Function Ratio at 5 days
Measure: Pulmonary Function Time: 5 days